Corcept Therapeutics Inc (NASDAQ:CORT) shares, rose in value, with the stock price up by 2.66% to the previous day’s close as strong demand from buyers drove the stock to $22.80.
Actively observing the price movement in the last trading, the stock closed the session at $22.21. The PE ratio was 24.05 over 12-month period. Referring to stock’s 52-week performance, its high was $34.28, and the low was $20.84. On the whole, CORT has fluctuated by -9.95% over the past month.
Projections by analysts suggest varying estimates for the company’s quarterly revenue. Analysts have estimated the company’s revenue for the quarter at 610.64M, with a low estimate of 136M and a high estimate of 145.84M. Wall Street analysts also predicted that the company’s y-o-y revenues would reach 141.2M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that CORT’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of CORT currently trading nearly -4.63% and -4.31% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 44.21, while the 7-day volatility ratio is showing 6.18% which for the 30-day chart, stands at 4.20%. Furthermore, Corcept Therapeutics Inc (CORT)’s beta value is 0.51, and its average true range (ATR) is 1.05.
A comparison of Corcept Therapeutics Inc (CORT) with its peers suggests the former has fared considerably weaker in the market. CORT showed an intraday change of 2.66% in last session, and over the past year, it grew by 2.56%%.
Data on historical trading for Corcept Therapeutics Inc (NASDAQ:CORT) indicates that the trading volumes over the past 3 months, they’ve averaged 1.18 million. According to company’s latest data on outstanding shares, there are 103.41 million shares outstanding.
Nearly 13.84% of Corcept Therapeutics Inc’s shares belong to company insiders and institutional investors own 80.85% of the company’s shares. The stock has fallen by -29.80% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the CORT stock heading into the next quarter.
